Trade Pact War: Generic Stakeholders Push For Changes To US-Mexico-Canada Deal, Seek FDA Intervention

 
• By Brenda Sandburg

AAM wants Orange Book-like registry of patents and exclusivities, Bolar and "best mode" provisions; consulting group urges FDA to step in and ensure the trade pact does not benefit originators over generic/biosimilar makers.

USMCA or the new NAFTA United States Mexico Canada agreement symbol with north america flags as a trade deal and economic deal for the American Mexican and Canadian governments as a 3D illustration.

More from Biosimilars

More from Biosimilars & Generics